Emerging drugs for the treatment of gastroparesis

Bibliography

• Jung HK, Choung RS, Locke GR, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009;136:1225-33
   PubMed Web of Science ®Google Scholar
• Choung RS, Locke GR, Scleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012;107:82-8
   PubMed Web of Science ®Google Scholar
• Hasler WL, Wilson LA, Parkman HP, et al. Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil 2013;25:427-38
   PubMed Web of Science ®Google Scholar
• Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol 2010;8:676-81
   PubMed Web of Science ®Google Scholar
• Cherian D, Parkman HP. Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterol Motil 2012;24:217-22
   PubMed Web of Science ®Google Scholar
• Hasler WL, Wilson LA, Parkman HP, et al. Bloating in gastroparesis: severity, impact, and associated factors. Am J Gastroenterol 2011;106:1492-502
   PubMed Web of Science ®Google Scholar
• Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011;140:101-15
   PubMed Web of Science ®Google Scholar
• Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 2011;141:486-98
   PubMed Web of Science ®Google Scholar
• Reddymasu SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J Clin Gastroenterol 2010;44:e8-13
   PubMedGoogle Scholar
• Cherian D, Paladuou S, Pathikonda M, Parkman HP. Fatigue: a prevalent symptom in gastroparesis. Dig Dis Sci 2012;57:2088-95
   PubMed Web of Science ®Google Scholar
• Hasler WL, Parkman HP, Wilson LA, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol 2010;105:2357-67
   PubMed Web of Science ®Google Scholar
• Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil 2006;18:433-40
   PubMed Web of Science ®Google Scholar
• Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat Rev Gastroenterol Hepatol 2011;8:438-53
   PubMed Web of Science ®Google Scholar
• Kofod-Andersen K, Tarnow L. Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes. J Diabetes Complications 2012;26:89-93
   PubMed Web of Science ®Google Scholar
• Trus TL, Bax T, Richardson WS, et al. Complications of laparoscopic paraesophageal hernia repair. J Gastrointest Surg 1997;1:221-8
   PubMedGoogle Scholar
• Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986;90:1919-25
   PubMed Web of Science ®Google Scholar
• Gaddipati KV, Simonian HP, Kresge KM, et al. Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. Dig Dis Sci 2006;51:1339-46
   PubMed Web of Science ®Google Scholar
• Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011;140:1575-85
   PubMed Web of Science ®Google Scholar
• Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-62
   PubMed Web of Science ®Google Scholar
• Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008;103:753-63
   PubMed Web of Science ®Google Scholar
• Sachdeva P, Malhotra N, Pathikonda M, et al. Gastric emptying of solids and liquids for evaluation for gastroparesis. Dig Dis Sci 2011;56:1138-46
   PubMed Web of Science ®Google Scholar
• Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2008;27:186-96
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008;6:635-43
   PubMed Web of Science ®Google Scholar
• Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index—Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012;24:456-63
   PubMed Web of Science ®Google Scholar
• Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011;9:1056-64
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Nguyen LA, Snape WJ, et al. Changes in quality of life and symptoms in a large cohort of patients with gastroparesis followed prospectively for 48 weeks (abstract). Gastroenterology 2010;138:1069
   Google Scholar
• Anaparthy R, Pehlivanov N, Grady J, et al. Gastroparesis and gastroparesis-like syndrome: response to therapy and its predictors. Dig Dis Sci 2009;54:1003-10
   PubMed Web of Science ®Google Scholar
• Uppalapati SS, Ramzan Z, Fisher RS, Parkman HP. Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci 2009;54:2404-9
   PubMed Web of Science ®Google Scholar
• Jones KL, Russo A, Berry MK, et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med 2002;113:449-55
   PubMed Web of Science ®Google Scholar
• Chang J, Rayner CK, Jones KL, Horowitz M. Prognosis of diabetic gastroparesis—a 25 year evaluation. Diabet Med 2013;30:e185-8
   PubMed Web of Science ®Google Scholar
• Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 2013;168:1859-67
   PubMed Web of Science ®Google Scholar
• Javid FA, Bulmer DC, Broad J, et al. Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. Eur J Pharmacol 2013;699:48-54
   PubMed Web of Science ®Google Scholar
• Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008;6:726-33
   PubMed Web of Science ®Google Scholar
• Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12
   PubMed Web of Science ®Google Scholar
• Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 2007;52:418-24
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006;47:440-2
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2014; In press
   Web of Science ®Google Scholar
• Friedenberg FK, Palit A, Parkman HP, et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008;103:416-23
   PubMed Web of Science ®Google Scholar
• Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003;125:421-8
   PubMed Web of Science ®Google Scholar
• McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010;8:947-54
   PubMed Web of Science ®Google Scholar
• McCallum RW, Sarosiek I, Parkman HP, et al. Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterol Motil 2013;25:815-e636
   PubMed Web of Science ®Google Scholar
• Hibbard ML, Dunst CM, Swanstrom LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg 2011;15:1513-19
   PubMed Web of Science ®Google Scholar
• Haniadka R, Rajeev A, Govindaraju P, et al. Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review. J Altern Complement Med 2012;18:440-4
   PubMed Web of Science ®Google Scholar
• Braden B, Caspary W, Borner N, et al. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009;21:632-8
   PubMed Web of Science ®Google Scholar
• Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab 2010;5:653-62
   PubMedGoogle Scholar
• Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 2013;108:866-72
   PubMed Web of Science ®Google Scholar
• Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol 2008;103:313-22
   PubMed Web of Science ®Google Scholar
• Nusrat S, Bielefeldt K. Gastroparesis on the rise: incidence vs. awareness? Neurogastroenterol Motil 2013;25:16-22
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 2011;9:567-76
   PubMed Web of Science ®Google Scholar
• Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004;127:1685-94
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Caenepeel P, Arts J, Tack J. Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut 2007;56:29-36
   PubMed Web of Science ®Google Scholar
• Kumar A, Attaluri A, Hashmi S, et al. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008;20:635-42
   PubMed Web of Science ®Google Scholar
• Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci 2009;54:2634-42
   PubMed Web of Science ®Google Scholar
• Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-67
   PubMed Web of Science ®Google Scholar
• Uchida M, Yamato S, Shimizu K, et al. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci 2013;121:282-7
   PubMed Web of Science ®Google Scholar
• Priem E, Van Colen I, De Maeyer JH, Lefebvre RA. The facilitating effect of prucalopride on cholinergic neurotransmission in pig gastric circular muscle is regulated by phosphodiesterase 4. Neuropharmacology 2012;62:2126-35
   PubMed Web of Science ®Google Scholar
• McKinnell RM, Armstrong SR, Beattie DT, et al. Discovery of TD-8954, a clinical stage 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett 2013;23:4210-15
   PubMed Web of Science ®Google Scholar
• Cho KH, Sung HJ, Son J, et al. DA-6650 maleate, a potent 5-HT4 receptor agonist, accelerated normal gastric emptying and restored delayed gastric emptying induced by cisplatin in the SD rat (abstract). Gastroenterology 2010;138:W1397
   Google Scholar
• Takahashi N, Yamamoto T, Watanabe S. RQ-00000010, the novel 5-HT4 receptor partial agonist, enhances clonidine-induced hypomotility and delayed gastric emptying in dogs (abstract). Gastroenterology 2012;142:Tu1458
   Google Scholar
• Talley NJ, Verlinden M, Geenen DJ, et al. Effect of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001;49:395-401
   PubMed Web of Science ®Google Scholar
• McCallum RW, Cynshi O; US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007;26:107-16
   PubMed Web of Science ®Google Scholar
• Leming S, Broad J, Cozens SJ, et al. GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011;23:958-e410
   PubMed Web of Science ®Google Scholar
• Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-6
   PubMed Web of Science ®Google Scholar
• Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012;18:7371-7
   PubMed Web of Science ®Google Scholar
• Wang L, Murphy NP, Stengel A, et al. Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats. Neurogastroenterol Motil 2012;24:e235-45
   PubMed Web of Science ®Google Scholar
• Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54:1693-8
   PubMed Web of Science ®Google Scholar
• Tyler KR, Mohammadi E, Pietra C, et al. Prokinetic effect of ipamorelin, a novel ghrelin agonist, in a rodent model of delayed gastric emptying (abstract). Gastroenterology 2010;138:W1774
   Google Scholar
• Datta R, Soulard C, Teillot M, et al. RM-131: a potent gastroprokinetic agent (abstract). Gastroenterology 2011;140:99
   Google Scholar
• Tack J, Janssen P. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Exp Opin Investig Drugs 2011;20:701-12
   PubMed Web of Science ®Google Scholar
• Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol 2011;666:218-25
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther 2011;336:791-800
   PubMed Web of Science ®Google Scholar
• Leslie RA, Reynolds DJ, Andrews PL, et al. Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience 1990;38:667-73
   PubMed Web of Science ®Google Scholar
• Costall B, Naylor RJ. Neuropharmacology of emesis in relation to clinical response. Br J Cancer Suppl 1992;19:S2-7
   PubMedGoogle Scholar
• Onishi T, Mori T, Yanagihara M, et al. Similarities of the neuronal circuit for the induction of fictive vomiting between ferrets and dogs. Auton Neurosci 2007;136:20-30
   PubMed Web of Science ®Google Scholar
• Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast)—a safe and effective standard in the treatment of functional gastrointestinal disorders. Wein Med Wochenschr 2013;163:65-72
   PubMedGoogle Scholar
• Yanai M, Mochiki E, Ogawa A, et al. Intragastric administration of rikkunshito stimulates upper gastrointestinal motility and gastric emptying in conscious dogs. J Gastroenterol 2013;48:611-19
   PubMed Web of Science ®Google Scholar
• Shim WS, Back H, Jung SW, et al. An aqueous extract of Poncirus fructus activates the prokinetic activity of 5-HT receptor subtype 4 without hERG interaction. J Ethnopharmacol 2010;132:328-33
   PubMed Web of Science ®Google Scholar
• Jang Y, Kim SW, Oh J, et al. Ghrelin receptor is activated by naringin and naringenin, constituents of a prokinetic Poncirus fructus. J Ethnopharmacol 2013;148:459-65
   PubMed Web of Science ®Google Scholar
• Jung YS, Kim MY, Lee HS, et al. Effect of DA-9701, a novel prokinetic agent, on stress-induced delayed gastric emptying and hormonal changes in rats. Neurogastroenterol Motil 2013;25:254-9
   PubMed Web of Science ®Google Scholar
• Jin YR, Jin J, Piao XX, Jin HG. The effect of Taraxacum officinale on gastric emptying and smooth muscle motility in rodents. Neurogastroenterol Motil 2011;23:766-e333
   PubMed Web of Science ®Google Scholar
• Kashyap PC, Choi KM, Dutta N, et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G1013-19
   PubMed Web of Science ®Google Scholar
• Choi KM, Sha L, Verhulst PJ, et al. Treatment with IL-10 reverses gastroparesis in diabetic NOD/Shiltj mice (abstract). Gastroenterology 2012;142:276
   Google Scholar
• Kusunoki H, Haruma K, Hata J, et al. Efficacy of mosapride citrate in proximal gastric accommodation and gastrointestinal motility in healthy volunteers: a double-blind placebo-controlled ultrasonographic study. J Gastroenterol 2010;45:1228-34
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects (abstract). Gastroenterology 2013;144:745
   Google Scholar
• Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-9
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Tajimi M, Takahashi N, et al. First in-human study of the novel 5-HT4 agonist, RQ-00000010, demonstrated acceleration of gastric emptying following single and multiple oral administration to healthy human subjects (abstract). Gastroenterology 2013;144:Mo2080
   Google Scholar
• Hellstrom P, Tack JF, Stephens KE, et al. A double-blind, randomized placebo-controlled phase II study of the pharmacodynamics, safety/tolerability, and pharmacokinetics of single doses of the motilin agonist GSK962040, in patients with type 1 diabetes mellitus (T1DM) and gastroparesis (abstract). Gastroenterology 2011;140:Tu1389
   Google Scholar
• Parkman HP, Carlson MR, Gonyer D. Metoclopramide for diabetic gastroparesis: comparison of a nasal spray formulation to conventional oral tablet administration [abstract]. Gastroenterology 2013;144:Mo2057
   Google Scholar
• Ejskjaer N, Vestergaard E, Hellstrom P, et al. Ghrelin agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis: an exploratory, randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:1179-87
   PubMed Web of Science ®Google Scholar
• Wo JM, Ejskjaer N, Hellstrom P, et al. Randomized clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting—randomized clinical study subset data. Aliment Pharmacol Ther 2011;33:679-88
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e140-50
   PubMed Web of Science ®Google Scholar
• McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e705-17
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11:1453-9
   PubMed Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-5
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia—100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173
   PubMed Web of Science ®Google Scholar
• Simmons K, Parkman HP. Granisetron transdermal patch for treatment of nausea and vomiting in gastroparesis: response to treatment using the clinical patient grading assessment scale (CPGAS) (abstract). Gastroenterology 2013;144:Mo2069
   Google Scholar
• Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother 2012;46:e38
   PubMedGoogle Scholar
• Hu ML, Rayner CK, Wu KL, et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol 2011;17:105-10
   PubMed Web of Science ®Google Scholar
• McCallum RW, Zarling EJ, Goetsch AC, et al. Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci 2010;340:259-63
   PubMed Web of Science ®Google Scholar
• Gomez R, Fernandez S, Azpirot A, et al. Effects of amoxicillin/clavulanate on gastrointestinal motility in children. J Pediatr Gastroenterol Nutr 2012;54:780-4
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-45
   PubMed Web of Science ®Google Scholar
• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-87
   PubMed Web of Science ®Google Scholar
• Kedar A, Nikitina Y, Martin E, et al. Immunomodulation for treatment of drug and device refractory gastroparesis: an open label pilot study of GAD65 positive patients (abstract). Gastroenterology 2013;144:Tu2107
   Google Scholar
• Bottoli I, Tougas G, Dunger-Baldauf C, et al. Efficacy of tegaserod over 12 months in IBS-C patients: do responders at 3 months still respond at month 12?(abstract). Gastroenterology 2005;128:A463
   PubMed Web of Science ®Google Scholar
• Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 2013;58:150-6
   PubMed Web of Science ®Google Scholar